GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Capex-to-Operating-Income

Egetis Therapeutics AB (OSTO:EGTX) Capex-to-Operating-Income : 0.00 (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Egetis Therapeutics AB's Capital Expenditure for the three months ended in Sep. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was kr-81.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Egetis Therapeutics AB Capex-to-Operating-Income Historical Data

The historical data trend for Egetis Therapeutics AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Capex-to-Operating-Income Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Egetis Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egetis Therapeutics AB's Capex-to-Operating-Income

For the Biotechnology subindustry, Egetis Therapeutics AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Capex-to-Operating-Income falls into.



Egetis Therapeutics AB Capex-to-Operating-Income Calculation

Egetis Therapeutics AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -320.3
=N/A

Egetis Therapeutics AB's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -81
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB  (OSTO:EGTX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Egetis Therapeutics AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines